Gynoconazol Vaginal Cream & Suppository
Terconazole (For vaginal use only)
Gynoconazol 0.4% vaginal cream: contains 0.4%
of the antifungal agent terconazole.
Gynoconazol 0.8% vaginal cream: contains 0.8%
of the antifungal agent terconazole.
Gynoconazol 80 vaginal suppository: contains
80 mg of the antifungal agent terconazole
Terconazole exhibits fungicidal activity in vitro against candida albicans. Antifungal activity has also been demonstrated againsl.QtlJ.er fungi.
Lactobacillus spp., beneficial bacteria found in the human vagina, are not affected by terconazole treatment. Terconazole may exert its antifungal activity by the disruption of normal fungal cell membrane permeability. No resistance to terconazole has developed during successive passages of candida albicans.
Gynoconazol 0.4% Vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (monilliasis). Activity also has been demonstrated
against other fungi. Gynoconazol 0.8% Vaginal cream and Gynoconazol 80 vaginal suppository are indicated for the local treatment & prophylaxis of vulvovaginal candidiasis (monilliasis) activity as well as other
SIDE EFFECTC :
Side effects are rare & mild in most cases. Most frequently reported were local irritation, pruritis & burning sensation especially at the start of the treatment. Complaints of abdominal pain, fever & skin rash have been reported.
The treatment should be discontinued if local irritation reaction, fever or chills occurred. General hygienic measures should be observed to control sources of
infection & re-infection. Appropriate therapy is indicated if the sexual partner is also infected.
PREGNANCY & LACTATION:
There are no adequate and controlled studies to date using intravaginal terconazole in women during the first trimester of pregnancy. The drug has been used intravaginally during the second and third trimester of pregnancy without adverse effects on the outcome of pregnancy. However, the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
– There was no evidence of teratogenicity when terconazole was administered.
Mutagenicity & Carcinogenicity:
There was no evidence of mutagenicity and carcinogenicity.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for adverse reaction in nursing infants from terconazole, a-decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother.
DOSAGE & ADMINISTRATION:
Gynoconazol 0.4% Vaginal Cream:
– One full applicator (5 g) should be administered intravaginally once daily at bedtime for seven consecutive days.
Gynoconazol 0.8% Vaginal Cream:
-Treatment: One full applicator (5 g) should be administered intravaginally once daily at bedtime for three consecutive days.
-Prophylaxis: One full applicator (5 g) should be administered intravaginally once weekly at bedtime.
Gynoconazol 80 Vaginal Suppository:
One vaginal suppository should be administered intravaginally once daily at bedtime for three consecative days
The therapeutic effect of these products is not affected by menstruation.
T erconazole vaginal cream and suppositories are contraindicated in individuals who have shown hypersensitivity to terconazole or to any other
ingredient of the creams or suppositories.
Gynoconazol 0.4%: 30g tubes with measured-dose applicator.
Gynoconazol 0.8%: 30 g tubes with measured-dose applicator.
Gynoconazol 80 : 3 vaginal suppositories.
KEEP ALL MEDICINES OUT OF REACH OF CHILDREN
Manufactured by :
Multi-Apex Pharma S_A_E –
Badr city – Cairo – Egypt.